Beta-1 blocker improves survival of septic rats through preservation of gut barrier function
Beta-1 blocker improves survival of septic rats through preservation of gut barrier function
复制标题
DOI：
10.1007/s00134-011-2326-x
复制
发表时间：
2011-11-01
影响因子：
38.9
通讯作者：
Takeda, Junzo
中科院分区：
文献类型：
--
作者：
Mori, Katsuya;Morisaki, Hiroshi;Takeda, Junzo
目的：由于最近的研究证明了β-肾上腺素能受体阻滞剂在脓毒症中的有益作用，我们检验了输注选择性β 1受体阻滞剂艾司洛尔通过调节炎症反应和肠道屏障功能改善脓毒症结局的假设。设计：前瞻性随机动物研究。设置：大学研究实验室。受试者：雄性Wistar大鼠。干预措施：为了评估艾司洛尔输注对生存时间的影响，将19只接受盲肠结扎和穿孔的动物随机分为对照组（n = 9）或艾司洛尔组（n = 10），后者在整个研究期间接受艾司洛尔输注（15 mg/kg/h）。在另外20只动物中，测量血浆和腹腔液中肿瘤坏死因子-α（TNF-α）的水平，并切除肠系膜淋巴结（MLN）和回肠，以评价18小时研究期间的细菌移位和粘膜损伤。测量和结果：艾司洛尔组的平均生存时间显著长于对照组（69.5 +/- 26.8 vs 28.6 +/- 11.0 h）。两组中均未检测到血浆TNF-α，而对照组腹腔液TNF-α水平升高，但艾司洛尔组显著降低（16.8 ± 10.7 vs 5.4 ± 7.1 pg/ml，P
Objective: Since recent study demonstrated beneficial effects of beta-adrenergic blocker in sepsis, we tested the hypothesis that infusion of selective beta 1-blocker, esmolol, improves outcome in sepsis by modulating inflammatory responses and gut barrier function. Design: Prospective randomized animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: To assess the effects of esmolol infusion on survival time, 19 animals that underwent cecal ligation and perforation were randomized into control (n = 9) or esmolol (n = 10) groups, the latter of which received esmolol infusion (15 mg/kg/h) throughout the study period. In an additional 20 animals, levels of tumor necrosis factor-alpha (TNF-alpha) in both plasma and intraperitoneal fluid were measured, and mesenteric lymph nodes (MLNs) and ileum were excised for evaluation of bacterial translocation and mucosal injury at the 18-h study period. Measurements and results: Mean survival time in the esmolol group was significantly longer compared with the control group (69.5 +/- 26.8 versus 28.6 +/- 11.0 h). Plasma TNF-alpha was not detectable in either group, while intraperitoneal fluid TNF-alpha level was elevated in the control group but significantly depressed in the esmolol group (16.8 +/- 10.7 versus 5.4 +/- 7.1 pg/ml, P